Compare · EWTX vs NVO
EWTX vs NVO
Side-by-side comparison of Edgewise Therapeutics Inc. (EWTX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EWTX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.82B, about 54.3x EWTX ($3.39B).
- Over the past year, EWTX is up 101.1% and NVO is down 34.2% - EWTX leads by 135.4 points.
- NVO has been more active in the news (5 items in the past 4 weeks vs 2 for EWTX).
- NVO has more recent analyst coverage (25 ratings vs 15 for EWTX).
- Company
- Edgewise Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $31.58+1.19%
- $41.18+6.93%
- Market cap
- $3.39B
- $183.82B
- 1M return
- -1.11%
- +13.32%
- 1Y return
- +101.15%
- -34.24%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 2
- 5
- Recent ratings
- 15
- 25
Edgewise Therapeutics Inc.
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. It offers a precision medicine muscle platform that generates programs to address various muscle disorders, such as Duchenne, Becker, and limb girdle muscular dystrophies. The company develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was founded in 2017 and is headquartered in Boulder, Colorado.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest EWTX
- SEC Form DEFA14A filed by Edgewise Therapeutics Inc.
- SEC Form DEF 14A filed by Edgewise Therapeutics Inc.
- SEC Form 4 filed by Fox Jonathan C
- SEC Form 4 filed by Donovan Joanne M.
- Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
- SEC Form 4 filed by Donovan Joanne M.
- SEC Form 4 filed by Donovan Joanne M.
- SEC Form 144 filed by Edgewise Therapeutics Inc.
- Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up
- Edgewise Therapeutics to Present at the Leerink Global Healthcare Conference on March 11, 2026
Latest NVO
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Wolfe Research initiated coverage on Novo Nordisk A/S